FDMT Historical Cash Flow
| FDMT Stock | USD 7.50 0.12 1.57% |
Analysis of 4D Molecular cash flow over time is an excellent tool to project 4D Molecular Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 20.6 M or Change In Working Capital of 661.5 K as it is a great indicator of 4D Molecular ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining 4D Molecular Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether 4D Molecular Therapeutics is a good buy for the upcoming year.
FDMT |
About FDMT Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in FDMT balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which FDMT's non-liquid assets can be easily converted into cash.
4D Molecular Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by 4D Molecular Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of 4D Molecular operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from 4D Molecular's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into 4D Molecular Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in 4D Molecular Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. At this time, 4D Molecular's Change To Netincome is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 800.4 K in 2024, whereas Total Cashflows From Investing Activities is likely to drop (16.1 M) in 2024.
4D Molecular cash flow statement Correlations
Click cells to compare fundamentals
4D Molecular Account Relationship Matchups
High Positive Relationship
High Negative Relationship
4D Molecular cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 175K | 2.9M | (591K) | (4.5M) | (4.1M) | (3.9M) | |
| Investments | (3.2M) | (1M) | (163.6M) | (5.5M) | 86.6M | 91.0M | |
| Change In Cash | (42.1M) | 227.1M | (123.7M) | (100.7M) | 196.8M | 206.6M | |
| Stock Based Compensation | 3.5M | 5.0M | 13.8M | 17.1M | 19.7M | 20.6M | |
| Free Cash Flow | (39.9M) | (51.9M) | (78.2M) | (98.2M) | (78.6M) | (82.5M) | |
| Change In Working Capital | 259K | (711K) | (15.5M) | (1.3M) | 630K | 661.5K | |
| Begin Period Cash Flow | 91.8M | 49.7M | 276.7M | 153.0M | 52.4M | 103.0M | |
| Total Cashflows From Investing Activities | (3.2M) | (1M) | (172.7M) | (17.1M) | (15.3M) | (16.1M) | |
| Other Cashflows From Financing Activities | (2.3M) | 73.3M | 3.8M | 3.1M | 8.5M | 8.1M | |
| Depreciation | 1.0M | 1.4M | 3.0M | 3.9M | 5.7M | 6.0M | |
| Other Non Cash Items | 5.1M | 48K | 898K | 1.1M | (999K) | (949.1K) | |
| Capital Expenditures | 3.2M | 1M | 9.1M | 11.5M | 2.8M | 4.5M | |
| Total Cash From Operating Activities | (36.7M) | (50.9M) | (69.1M) | (86.7M) | (75.8M) | (72.0M) | |
| Change To Account Receivables | (803K) | 146K | (508K) | 1.4M | 47K | 0.0 | |
| Change To Operating Activities | 2.9M | (591K) | (4.5M) | 3.4M | 3.0M | 3.2M | |
| Net Income | (49.3M) | (56.7M) | (71.3M) | (107.5M) | (100.8M) | (95.8M) | |
| Total Cash From Financing Activities | (2.2M) | 279.0M | 118.1M | 3.1M | 156.8M | 100.5M | |
| End Period Cash Flow | 49.7M | 276.7M | 153.0M | 52.4M | 249.1M | 140.9M | |
| Change To Netincome | 8.7M | 5.1M | 14.7M | 17.1M | 19.7M | 20.7M | |
| Change To Liabilities | (2.8M) | 388K | (12.4M) | 847K | 762.3K | 800.4K | |
| Issuance Of Capital Stock | 75K | 278.1M | 114.3M | 9.6M | 148.3M | 116.4M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.